Acorda Therapeutics Inc.

Development and marketing of therapies to restore neurological function

Acorda Therapeutics was established in 1995.

Ron Cohen, MD, President, CEO
Andrew R. Blight, PhD., CSO
Mary Fisher, COO
David Lawrence, M.B.A, CFO

Ron Cohen, M.D.
Standish M. Fleming
John Friedman
Sandra Panem, PhD
Barclay Phillips
Mark R. E. Pinney
Steven M. Rauscher
Michael Steinmetz, Ph.D.
Wise Young, M.D., Ph.D.
Lorin J. Randall

Michael S. Beattie, Ph.D.
Jacqueline C. Bresnahan, Ph.D.
Mary B. Bunge, Ph.D.
Carl W. Cotman, Ph.D.
James Fawcett, Ph.D.
Martin Grumet, Ph.D.
Eugene Johnson, Jr., Ph.D.
Mark D. Noble, Ph.D.
Melitta Schachner, Ph.D.
Patrick A. Tresco, Ph.D.
Jerry Silver, Ph.D.
Mark H. Tuszynski, Ph.D.
Stephen G. Waxman, M.D., Ph.D.
Wise Young, M.D., Ph.D.

15 Skyline Drive
Hawthorne, NY 10532
USA
Phone: +1-914-347-4300
Fax: +1-914-347-4560

Currently there is no therapy that improves neurological function in people with a long term, or chronic, SCI or with MS. Clinical trials of the company’s lead product, Fampridine-SR, have shown improvements in some neurological functions in people with these conditions. The company’s second most advanced product candidate, valrocemide, is being developed in collaboration with Teva Pharmaceuticals.

Fampridine-SR in Phase 3 clinical trials for spinal cord injury (SCI)
Fampridine-SR in Phase 2 clinical trials for multiple sclerosis (MS)
Valrocemide has completed a Phase 2 clinical trial in epilepsy

cytotoxic chemotherapy (clincial trial)
Bone Marrow Cells - Osteoporosis (clinical trial)
Apheresis Reduction - Lymphoma (clinical trial)
Apheresis Reduction - Breast Cancer (clinical trial)

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.